141 living cortical samples from neurosurgical patients, paired with MRI and multi-omics profiling across more than 100,000 cells, revealed senescence-associated gene activity in excitatory neurons that correlates with smaller cortical volumes and structural measures across the lifespan. The dataset constitutes a direct molecular-to-structure map built from living human brain tissue rather than postmortem material.
The Icahn School of Medicine at Mount Sinai’s Living Brain Project, supported by BPGbio, published the work in Cell, positioning a living-human-tissue platform as a foundation for translational discovery in neurodegeneration. Researchers integrated bulk RNA sequencing, proteomics, and single-nucleus RNA sequencing from tissue obtained during routine deep brain stimulation procedures with MRI-derived metrics of cortical area, thickness, and volume from the same individuals. Analyses point to shared molecular programs between development and aging, with cellular senescence emerging as a coordinated biological program rather than a passive marker, and with signals localized to specific cell types including excitatory neurons and microglia.
Strategically, this is a platform play aimed at reducing the disconnect between preclinical models and human disease biology that has driven attrition in neurology. By anchoring molecular signals to structural imaging within individuals, the effort seeks to generate targetable pathways and clinically tractable biomarkers that sponsors can prosecute and measure non-invasively. The involvement of an AI-enabled biopharma partner underscores an intent to convert a high-dimensional, human-derived dataset into a pipeline of targets and companion biomarkers, a bid to compress early discovery timelines and de-risk subsequent clinical development.
The move pressures sponsors and CROs to evolve operating models. For discovery groups, living human tissue tied to MRI offers a path to nominate targets with built-in translational readouts, inform enrichment strategies, and design earlier go/no-go milestones around imaging endpoints linked to cell-type–specific biology. CROs and imaging vendors may see demand for integrated omics–imaging workflows, centralized analysis pipelines, and biomarker operations that can support stratification or pharmacodynamic assessment in Phase 1–2 neurology programs. Academic and hospital sites with neurosurgical capacity become critical nodes for specimen collection, consent, rapid processing, and data governance, implying new SOPs, chain-of-custody rigor, and reimbursement models. Regulators are likely to evaluate whether MRI measures anchored in living-tissue biology can be advanced toward qualification as enrichment tools or pharmacodynamic surrogates, aligning with ongoing efforts to modernize biomarker use in neurodegeneration.
Key tensions remain around scalability and generalizability. Tissue from deep brain stimulation cohorts may not fully represent broader neurodegenerative populations, raising questions about cohort bias and the need for multi-center replication with diverse indications. Standardization of tissue handling, multi-omics methods, and imaging pipelines will determine reproducibility and eventual regulatory credibility. The central biological claim—that senescence programs actively shape structure and degeneration—will need prospective validation and demonstration that these pathways are modifiable in humans in ways that translate into functional benefit.
Watch for expansion of the Living Brain Project into multi-site networks, external validation in independent cohorts, and public or controlled-access data releases that enable cross-industry interrogation. On the development side, expect biomarker qualification efforts tying senescence signatures to MRI changes, early-phase trials that stratify by or modulate senescence-related pathways, and partnering announcements around targets emerging from the dataset. The near-term test is whether these living-tissue–anchored signals can yield actionable pharmacology and measurable, regulator-acceptable endpoints that shorten the path from discovery to proof of biology in patients.
Jon Napitupulu is Director of Media Relations at The Clinical Trial Vanguard. Jon, a computer data scientist, focuses on the latest clinical trial industry news and trends.
